We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Serum Biomarker Determined for Colorectal Cancer

By LabMedica International staff writers
Posted on 02 Jul 2013
A highly sensitive blood test can detect cancer related micro-ribonucleic acid (miRNA) before any signs of the disease manifests. More...


Increased expression of circulating miRNAs could be indicative of miRNAs secreted from a tumor, raising the overall diagnostic specificity of biomarkers, especially if they can be measured in blood or serum samples.

Scientists at the Baylor Research Institute (Dallas, TX, USA) analyzed 568 serum and tissue specimens that were obtained from healthy volunteers and consecutively enrolled patients with colorectal adenomas and cancers at the Mie University Medical Hospital (Tsu, Japan), between January 1, 2005 and December 31, 2010.

MiRNA extraction from serum and culture media samples was performed with miRNeasy RNA isolation Kits (Qiagen; Valencia, CA, USA), whereas miRNA extraction from formalin-fixed and paraffin-embedded (FFPE) samples was performed using RecoverAll Total Nucleic Acid Isolation Kits (Ambion Inc.; Austin, TX, USA). The TaqMan miRNA quantitative reverse-transcription polymerase chain reaction (qRT-PCR; Applied Biosystems; Foster City, CA, USA) were used to detect and quantify miRNA expression.

By measuring levels of miR-21 in the blood, the scientists could accurately identify up to 92% of patients with colorectal cancer. Even more importantly, not only is this test good for noninvasively identifying patients who already have colorectal cancer, but it can accurately identify up to 82% of patients with advanced colonic polyps, which present the highest risk for developing into colorectal cancers several years later in life.

Ajay Goel, PhD, the lead investigator said, “The development of this biomarker is highly encouraging because high mortality rates associated with colorectal cancer is a consequence of late detection of this disease, underscoring the need for improved early detection, prevention, risk assessment, and intervention. Michael Ramsay, MD, the president of Baylor Research Institute, added, “This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars.” The study was published on May 23, 2013, in the Journal of the National Cancer Institute.

Related Links:

Baylor Research Institute
Mie University Medical Hospital
Qiagen



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Immunofluorescence Analyzer
IFA System
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.